Download pdf
The treatment of lung cancer by gene editing technology and its comparison with traditional therapies
- 1 Nanjing University of Information Science & Technology
* Author to whom correspondence should be addressed.
Abstract
In the past, drug resistance in the anti-cancer process has been a major factor affecting the treatment of non-small cell lung cancer, which has greatly reduced the quality of life of patients, accompanied by greater suffering and lower survival rates. This article mainly discusses the possibility and practical feasibility of gene editing technology for curing some types of cancer under the current state of technology, and through analysis it finds that gene editing technology can greatly improve the negative effects of traditional drug treatment and chemotherapy, but the relatively immature technology and high cost often discourage many people. There are already experimented ways to cure cancer. For example, CRISPR-Cas9 gene editing technology is currently the easiest, most efficient, and most diverse way to edit genomes, and it is also one of the most attractive applications. It is hoped that it will be promoted and applied in the future while reducing costs.
Keywords
Lung cancer, Treatment, Gene editing technology, CRISPR-Cas9.
[1]. Wen, M., Yongqin, Y., Meitao, S., Xiaoqian, D., Zefang, Y., Xiaojuan, Z., & Wei, X. Research progress of CRISPR-Cas9 gene editing technology in tumor gene therapy. [J] Journal of Pingdingshan University, 33(2), 61-66 (2017).
[2]. Yang, Z., & Lin, C. (2018). Present Situation and Progress of Lung Cancer Therapy. [J] Advances in Clinical Medicine, 8(9), 27497. https://doi.org/10.12677/ACM.2018.89140.
[3]. ]Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J. Cancer incidence and mortality in China, 2022. [J] Journal of the National Cancer Center, 4(1), 47-53 (2024). https://doi.org/10.1016/j.jncc.2024.01.006.
[4]. Karasaki, T., Moore, D. A., & Others. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. [J] Nature Medicine, 29, 833–845 (2023). https://doi.org/10.1038/s41591-023-02230-w.
[5]. Lastwika, K. J. et al. Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non-small cell lung cancer. [J] Cancer Res. 76, 227–238 (2016).
[6]. Zhao, Q., Li, T., Chen, G., Zeng, Z., & He, J. Prognosis and risk factors of radiation-induced lymphopenia in early-stage lung cancer treated with stereotactic body radiation therapy. [J] Frontiers in Oncology, 9, 1488 (2019). https://doi.org/10.3389/fonc.2019.01488
[7]. Li, Y., Fan, X., Pei, Y., Yu, Q., Lu, R., Jiang, G., & Wu, K. The impact of different modalities of chemoradiation therapy and chemotherapy regimens on lymphopenia in patients with locally advanced non-small cell lung cancer. [J] Translational Lung Cancer Research, 13(6), 1190-1200 (2024). https://dx.doi.org/10.21037/tlcr-24-60
[8]. Yoshikawa, S., Kawakami, K., & Zhao, X. C. G2R Cre Reporter Transgenic Zebrafish. PubMed Central, 237(9), 2460-2465 (2008).
[9]. Zeng, H. M., & Chen, W. Q. Current status of cancer epidemiology and prevention research in China. Chemical Progress, 25(9), 1415-1420 (2013).
[10]. Wang, D. Y., Ma, N., & Hui, Y. Application of CRISPR/Cas9 genome-editing technology in cancer research. Hereditas (Beijing), 38(1), 1-8 (2016).
[11]. Lu, Y. R. The effect of CRISPR/Cas9-mediated SMYD3 gene knockout on human lung cancer cells. Inner Mongolia University (2016).
Cite this article
Lou,L. (2024). The treatment of lung cancer by gene editing technology and its comparison with traditional therapies. Theoretical and Natural Science,60,58-63.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).